

# Arnulf Stenzl

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9196005/arnulf-stenzl-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212  
papers

6,242  
citations

37  
h-index

74  
g-index

240  
ext. papers

7,776  
ext. citations

4.6  
avg, IF

5.61  
L-index

#	Paper	IF	Citations
212	Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 115-115	2.2	0
211	The role of single-nucleotide polymorphisms of the 8q24 chromosome region in patients with concomitant bladder and prostate cancer.. <i>Scandinavian Journal of Urology</i> , <b>2022</b> , 1-5	1.6	0
210	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200193	2.2	5
209	Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues.. <i>Cell Transplantation</i> , <b>2022</b> , 31, 9636897221080943	4	
208	Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1
207	CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5453	6.3	1
206	Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 6305	6.3	1
205	Enfortumab vedotin - next game-changer in urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 801-809	5.4	4
204	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. <i>European Journal of Radiology</i> , <b>2021</b> , 146, 110059	4.7	0
203	Sensitivity and Specificity in Urine Bladder Cancer Markers ¶s it that Simple?. <i>Bladder Cancer</i> , <b>2021</b> , 1-4	1	
202	Minimal-invasive management of urological complications after kidney transplantation. <i>International Urology and Nephrology</i> , <b>2021</b> , 53, 1267-1277	2.3	2
201	Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?. <i>World Journal of Urology</i> , <b>2021</b> , 39, 4021-4027	4	
200	Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
199	Injection of Porcine Adipose Tissue-Derived Stromal Cells by a Novel Waterjet Technology. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
198	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 205, 1371	2.5	
197	The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5071-5071	2.2	
196	Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. <i>Journal of Urology</i> , <b>2021</b> , 205, 1361-1371	2.5	3

195	Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology. <i>Prostate International</i> , <b>2021</b> , 9, 61-65	3.4	5
194	Pembrolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1157-1164	5.4	1
193	Rapid and precise delivery of cells in the urethral sphincter complex by a novel needle-free waterjet technology. <i>BJU International</i> , <b>2021</b> , 127, 463-472	5.6	4
192	A Modified Neobladder Technique: The "I-Pouch" - Illustration of Surgical Approach and Tricks. <i>Urology</i> , <b>2021</b> , 147, 318	1.6	1
191	Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1685-1694	7.5	0
190	Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 41-51	2.8	29
189	Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer. <i>World Journal of Men's Health</i> , <b>2021</b> , 39, 38-47	6.8	2
188	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	6
187	Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. <i>World Journal of Urology</i> , <b>2021</b> , 39, 2953-2960	4	1
186	Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 102-102	2.2	1
185	The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3367-3376	4	1
184	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , <b>2021</b> , 80, 703-711	10.2	16
183	Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy. <i>Urologia Internationalis</i> , <b>2021</b> , 1-7	1.9	1
182	On the probability of lymph node negativity in pN0-staged prostate cancer—a theoretically derived rule of thumb for adjuvant needs. <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 1	4.3	
181	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 205, 114288	3.5	1
180	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 971-979	5.4	3
179	Prognostic significance of previous tonsillectomy after radical cystectomy for bladder cancer. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 297-303	1.6	
178	Re: Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy Versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. <i>European Urology</i> , <b>2020</b> , 77, 657-658	10.2	

177	Human Prostate Cancer is Characterized by an Increase in Urea Cycle Metabolites. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
176	Impact of Histopathological Prostate Inflammation on Urine-Based Prostate Cancer Prediction Using the Prostate Cancer Gene 3 Score. <i>Urologia Internationalis</i> , <b>2020</b> , 104, 483-488	1.9	
175	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. <i>Future Oncology</i> , <b>2020</b> , 16, 1511-1524	3.6	1
174	Regenerative medicine and injection therapies in stress urinary incontinence. <i>Nature Reviews Urology</i> , <b>2020</b> , 17, 151-161	5.5	9
173	Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 886-895	2.8	11
172	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , <b>2020</b> , 78, 603-614	10.2	7
171	Urothelial Cancer of the Upper Urinary Tract <b>2020</b> , 539-550		
170	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. <i>World Journal of Men's Health</i> , <b>2020</b> , 38, 151-163	6.8	3
169	Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5547-5547	2.2	0
168	Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. <i>Journal of Urology</i> , <b>2020</b> , 203, 62-72	2.5	20
167	A novel waterjet technology for transurethral cystoscopic injection of viable cells in the urethral sphincter complex. <i>Neurourology and Urodynamics</i> , <b>2020</b> , 39, 594-602	2.3	10
166	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , <b>2020</b> , 77, 223-250	10.2	60
165	Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	4
164	Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study. <i>Genes</i> , <b>2020</b> , 11,	4.2	2
163	Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	3
162	The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy. <i>World Journal of Urology</i> , <b>2020</b> , 38, 397-406	4	3
161	Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 4.e7-4.e15	2.8	1
160	Immune checkpoint inhibition for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 83-94	5.4	10

159	Re: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2020</b> , 77, 131-132	10.2	
158	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 61-83	4	31
157	Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 1835-1843	4.9	4
156	NLRP3/IL1 $\beta$ inflammasome associated with the aging bladder triggers bladder dysfunction in female rats. <i>Molecular Medicine Reports</i> , <b>2019</b> , 19, 2960-2968	2.9	3
155	Intention-to-Treat Analysis of Ga-PSMA and C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1359-1365	8.9	18
154	Antitumour activity of Helix hemocyanin against bladder carcinoma permanent cell lines. <i>Biotechnology and Biotechnological Equipment</i> , <b>2019</b> , 33, 20-32	1.6	8
153	Bone Target Therapy in Urologic Malignancies <b>2019</b> , 77-93		
152	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2974-2986	2.2	285
151	Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 687-687	2.2	18
150	ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5048-5048	2.2	1
149	Stress urinary incontinence and regenerative medicine: is injecting functional cells into the urethra feasible based on current knowledge and future prospects?. <i>Current Opinion in Urology</i> , <b>2019</b> , 29, 394-399	2.8	1
148	Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer. <i>Disease Markers</i> , <b>2019</b> , 2019, 1296865	3.2	1
147	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1773-1784	4	14
146	Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. <i>European Urology</i> , <b>2019</b> , 75, 604-611	10.2	112
145	Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1339-1346	4	9
144	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. <i>European Urology Focus</i> , <b>2019</b> , 5, 604-607	5.1	13
143	Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 240.e21-240.e26	2.8	1
142	Higher prevalence of lymph node metastasis in prostate cancer in patients with diabetes. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, L19-L22	5.7	11

141	Androgen receptor overexpression in prostate cancer in type 2 diabetes. <i>Molecular Metabolism</i> , <b>2018</b> , 8, 158-166	8.8	16
140	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. <i>BJU International</i> , <b>2018</b> , 122, 152-159	5.6	18
139	Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1. <i>Analytical Chemistry</i> , <b>2018</b> , 90, 5788-5794	7.8	6
138	Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 178-184	3.6	11
137	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 10.e7-10.e14	2.8	9
136	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. <i>Cancer Research</i> , <b>2018</b> , 78, 129-142	10.1	31
135	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , <b>2018</b> , 16, 108	11.4	5
134	Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 472.e21-472.e27	2.8	8
133	Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 54-59	2.8	15
132	Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. <i>BJU International</i> , <b>2018</b> , 121, 791-798	5.6	18
131	A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 43-53	2.8	61
130	Immunotherapy for kidney cancer: status quo and the future. <i>Current Opinion in Urology</i> , <b>2018</b> , 28, 8-14	2.8	20
129	Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer. <i>Diagnostic Cytopathology</i> , <b>2018</b> , 46, 111-116	1.4	4
128	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , <b>2018</b> , 121, 84-92	5.6	16
127	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2746-2755	6.1	34
126	Trimodal therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 1219-1229	3.2	2296
125	Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. <i>Disease Markers</i> , <b>2018</b> , 2018, 1874598	3.2	6
124	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. <i>Disease Markers</i> , <b>2018</b> , 2018, 5823870	3.2	15

123	Suture causing urethral meatus stricture: A novel animal model of partial bladder outlet obstruction. <i>Neurourology and Urodynamics</i> , <b>2018</b> , 37, 2088-2096	2.3	1
122	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 357-368	3.5	6
121	Total proximal ureter substitution using buccal mucosa. <i>International Journal of Urology</i> , <b>2017</b> , 24, 320-323		6
120	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 458.e1-458.e7	2.8	6
119	Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , <b>2017</b> , 9, 81-88	3.2	18
118	The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization. <i>Advances in Therapy</i> , <b>2017</b> , 34, 966-974	4.1	0
117	Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 677-685	4.9	12
116	Precise injection of human mesenchymal stromal cells in the urethral sphincter complex of Göttingen minipigs without unspecific bulking effects. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 1723-1733	3.3	11
115	Establishing and monitoring of urethral sphincter deficiency in a large animal model. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1977-1986	4	2
114	Ex vivo H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 386-394	5.3	12
113	Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer. <i>Prostate</i> , <b>2017</b> , 77, 1251-1258	4.2	2
112	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6487-6497	12.9	81
111	Assessing the reproducibility of high definition urethral pressure profilometry and its correlation with an air-charged system. <i>Neurourology and Urodynamics</i> , <b>2017</b> , 36, 1292-1300	2.3	2
110	Collagen cell carriers seeded with human urothelial cells for urethral reconstructive surgery: first results in a xenograft minipig model. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1125-1132	4	13
109	Comparison of Ga-labelled PSMA-11 and C-choline in the detection of prostate cancer metastases by PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 92-101	8.8	191
108	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , <b>2017</b> , 71, 545-557	10.2	46
107	AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2017</b> , 2, 243-248	1.6	
106	DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 516-516	2.2	2

105	Minimal Invasive Cystometry and Intra-Abdominal Pressure Assessments in Rodents: A Novel Animal Study. <i>Medical Science Monitor</i> , <b>2017</b> , 23, 2500-2507	3.2	1
104	Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes. <i>Anticancer Research</i> , <b>2017</b> , 37, 261-265	2.3	4
103	Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score. <i>Anticancer Research</i> , <b>2017</b> , 37, 1369-1373	2.3	14
102	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , <b>2017</b> ,	2.8	5
101	Bone Target Therapy in Urologic Malignancies <b>2017</b> , 1-16		
100	Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival. <i>International Journal of Urology</i> , <b>2016</b> , 23, 916-921	2.3	9
99	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. <i>BJU International</i> , <b>2016</b> , 118, 855-863	3.6	48
98	Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?. <i>Medical Hypotheses</i> , <b>2016</b> , 92, 57-8	3.8	7
97	Assessment of a new point-of-care system for detection of prostate specific antigen. <i>BMC Urology</i> , <b>2016</b> , 16, 4	2.2	3
96	Signal processing in urodynamics: towards high definition urethral pressure profilometry. <i>BioMedical Engineering OnLine</i> , <b>2016</b> , 15, 31	4.1	5
95	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , <b>2016</b> , 34, 97-103	4	37
94	Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 937-47	4.9	7
93	Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review. <i>European Urology</i> , <b>2016</b> , 70, 293-8	10.2	28
92	Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 263-71	4	4
91	Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>European Urology</i> , <b>2016</b> , 69, 538-9	10.2	2
90	Challenges for Restoration of Lower Urinary Tract Innervation in Patients with Spinal Cord Injury: A European Single-center Retrospective Study with Long-term Follow-up. <i>European Urology</i> , <b>2016</b> , 69, 771-4	10.2	8
89	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. <i>OncImmunology</i> , <b>2016</b> , 5, e1108511	7.2	23
88	Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4503-4503	2.2	24



87	Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163873	3.7	12
86	The Impact of Blue Light Cystoscopy with Hexaminolevulinat (HAL) on Progression of Bladder Cancer - A New Analysis. <i>Bladder Cancer</i> , <b>2016</b> , 2, 273-278	1	33
85	High definition urethral pressure profilometry: Evaluating a novel microtip catheter. <i>Neurourology and Urodynamics</i> , <b>2016</b> , 35, 888-894	2.3	6
84	The current status of checkpoint inhibitors in metastatic bladder cancer. <i>Clinical and Experimental Metastasis</i> , <b>2016</b> , 33, 629-35	4.7	9
83	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1204504	7.2	14
82	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. <i>European Urology</i> , <b>2016</b> , 70, 649-660	10.2	90
81	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1599-1611	21.7	121
80	Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma. <i>Anticancer Research</i> , <b>2016</b> , 36, 2865-293	3	3
79	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , <b>2015</b> , 68, 238-53	10.2	168
78	Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1429-37	4	22
77	Feasibility of Penis-Preserving Surgery for Urethral Melanoma: Proposal for a Therapeutic Algorithm. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e411-3	3.3	10
76	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , <b>2015</b> , 68, 1016-20	10.2	37
75	New technique for needle-less implantation of eukaryotic cells. <i>Cytotherapy</i> , <b>2015</b> , 17, 1655-61	4.8	6
74	Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 426.e21-9	2.8	3
73	Treatment and outcomes of urethral recurrence of urinary bladder cancer in women after radical cystectomy and orthotopic neobladder: a series of 12 cases. <i>Urologia Internationalis</i> , <b>2015</b> , 94, 45-9	1.9	11
72	Residual H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 116, 480-5	5.3	29
71	Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. <i>BJU International</i> , <b>2015</b> , 115, 14-23	5.6	38
70	Quality of life outcomes after radical cystectomy: long-term standardized assessment of Studer Pouch versus I-Pouch. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1381-7	4	10

69	Analysis of early morbidity and functional outcome of thulium: yttrium-aluminum-garnet laser enucleation for benign prostate enlargement: patient age and prostate size determine adverse surgical outcome. <i>Urology</i> , <b>2015</b> , 85, 182-8	1.6	31
68	Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 427-9	2.8	11
67	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study <b>2015</b> , 3, 26		133
66	Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. <i>International Journal of Endocrinology</i> , <b>2015</b> , 2015, 838202	2.7	25
65	Eliminating pulse-induced artifacts in Urethral Pressure data. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2015</b> , 2015, 2779-83	0.9	4
64	Mesenchymal stromal cells for sphincter regeneration. <i>Advanced Drug Delivery Reviews</i> , <b>2015</b> , 82-83, 123-36	18.5	19
63	Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , <b>2015</b> , 33, 1403-9	4	8
62	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , <b>2015</b> , 67, 363-75	10.2	128
61	Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. <i>European Urology</i> , <b>2015</b> , 67, 402-22	10.2	158
60	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4568-4568	2.2	1
59	Rho GDP dissociation inhibitor beta ARHGDI in renal cell cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 474-474	2.2	
58	Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study. <i>SpringerPlus</i> , <b>2014</b> , 3, 24		7
57	Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 337-44	2.8	30
56	Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. <i>European Urology</i> , <b>2014</b> , 66, 863-71	10.2	57
55	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1141-50	2.8	10
54	Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>Journal of Urology</i> , <b>2014</b> , 191, 316-22	2.5	39
53	GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma. <i>Oncology Reports</i> , <b>2014</b> , 31, 1523-30	3.5	12
52	Towards a Treatment of Stress Urinary Incontinence: Application of Mesenchymal Stromal Cells for Regeneration of the Sphincter Muscle. <i>Journal of Clinical Medicine</i> , <b>2014</b> , 3, 197-215	5.1	10

51	Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer. <i>Disease Markers</i> , <b>2014</b> , 2014, 973406	3.2	15
50	Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma. <i>BMC Clinical Pathology</i> , <b>2014</b> , 14, 15	3	15
49	Recapitulating the urinary bladder--where are we heading?. <i>Nature Reviews Urology</i> , <b>2014</b> , 11, 70-1	5.5	
48	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , <b>2014</b> , 113, 11-23	5.6	198
47	Sampling lattice and signal reconstruction in urodynamics <b>2014</b> ,		3
46	Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. <i>Urology</i> , <b>2014</b> , 84, 122-6	1.6	14
45	Intracorporeal ileal ureter replacement using laparoscopy and robotics. <i>Central European Journal of Urology</i> , <b>2014</b> , 67, 420-3	0.9	15
44	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4587-4587	2.2	1
43	Author's reply. <i>Central European Journal of Urology</i> , <b>2014</b> , 67, 426	0.9	
42	Impact on clinical prognosis using DNA methylation of the SLC16A3 promoter and expression of the human lactate transporter MCT4 in renal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 452-452	2.2	
41	Impact of altered Wnt1/Eatenin expression on clinicopathology and prognosis in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 465-465	2.2	
40	Latissimus dorsi detrusor myoplasty to restore voiding in patients with an acontractile bladder - fact or fiction?. <i>Current Urology Reports</i> , <b>2013</b> , 14, 426-34	2.9	14
39	Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?. <i>World Journal of Urology</i> , <b>2013</b> , 31, 345-50	4	16
38	Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. <i>European Urology</i> , <b>2013</b> , 64, 624-38	10.2	156
37	ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. <i>European Urology</i> , <b>2013</b> , 63, 45-57	10.2	290
36	Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1148-54	2.8	22
35	Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. <i>European Urology</i> , <b>2013</b> , 64, 846-54	10.2	261
34	Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival. <i>Blood</i> , <b>2013</b> , 122, 1040-1040	2.2	

33	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <i>World Journal of Urology</i> , <b>2012</b> , 30, 847-52	4	18
32	Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. <i>Journal of Urology</i> , <b>2012</b> , 188, 58-62	2.5	125
31	Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. <i>Urology</i> , <b>2012</b> , 79, 620-4	1.6	28
30	Stem cell therapy for voiding and erectile dysfunction. <i>Nature Reviews Urology</i> , <b>2012</b> , 9, 435-47	5.5	25
29	Urinary Incontinence and Retention in the Female Neobladder Why Does This Occur and Treatment Options?. <i>Current Bladder Dysfunction Reports</i> , <b>2012</b> , 7, 309-314	0.4	2
28	Bladder hypocontractility--extending the indication for LDDM. <i>Nature Reviews Urology</i> , <b>2012</b> , 9, 231	5.5	2
27	Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e50953	3.7	44
26	Functional detrusor myoplasty for bladder acontractility: long-term results. <i>Journal of Urology</i> , <b>2011</b> , 185, 593-9	2.5	32
25	Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. <i>European Urology</i> , <b>2011</b> , 59, 1009-18	10.2	465
24	Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2010</b> , 36, 537-47	2	37
23	Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , <b>2010</b> , 184, 1907-13	2.5	183
22	Ileal Neobladder and Its Variants. <i>European Urology Supplements</i> , <b>2010</b> , 9, 745-753	0.9	29
21	In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1176, 135-43	6.5	56
20	Editorial comment. <i>Journal of Urology</i> , <b>2009</b> , 182, 1317; discussion 1317	2.5	
19	Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. <i>BJU International</i> , <b>2008</b> , 102, 446-51	5.6	106
18	Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 347-55	4	40
17	Reply to Dr Schrader and Dr Miller's Letter to the Editor re: Udo Nagele, Markus Kuczyk, Aristotelis G. Anastasiadis, Karl-Dietrich Sievert, Jörg Seibold, Arnulf Stenzl. Radical Cystectomy and Orthotopic Bladder Replacement in Females. <i>Eur Urol</i> 2006;50;249-57. <i>European Urology</i> , <b>2007</b> , 51, 863-864	10.2	
16	Re: Pathologic guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. <i>European Urology</i> , <b>2007</b> , 51, 849-50	10.2	

15	Urinary diversion. <i>Urology</i> , <b>2007</b> , 69, 17-49	1.6	284
14	Radical cystectomy and orthotopic bladder replacement in females. <i>European Urology</i> , <b>2006</b> , 50, 249-57	10.2	22
13	Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 871-6	3.5	5
12	Cystectomy – Technical Considerations in Male and Female Patients. <i>EAU Update Series</i> , <b>2005</b> , 3, 138-146		26
11	Orthotopic bladder reconstruction in women—what we have learned over the last decade. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 47, 147-54	7	29
10	Free neurovascular transfer of latissimus dorsi muscle for the treatment of bladder acontractility: II. Clinical results. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2003</b> , 29, 179-80	2	1
9	The remnant urothelium after reconstructive bladder surgery. <i>European Urology</i> , <b>2002</b> , 41, 124-31	10.2	57
8	Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. <i>Cancer</i> , <b>2001</b> , 92, 1864-71	6.4	101
7	Reconstruction of the lower urinary tract using autologous muscle transfer and cell seeding: current status and future perspectives. <i>World Journal of Urology</i> , <b>2000</b> , 18, 44-50	4	15
6	Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle. <i>Lancet, The</i> , <b>1998</b> , 351, 1483-5	40	49
5	Free Neurovascular Transfer of Latissimus Dorsi Muscle to the Bladder. I. Experimental Studies. <i>Journal of Urology</i> , <b>1997</b> , 157, 1103-1108	2.5	48
4	Update of urethra-sparing approaches in cystectomy in women. <i>World Journal of Urology</i> , <b>1997</b> , 15, 134-8		55
3	Rationale and Technique of Nerve Sparing Radical Cystectomy Before an Orthotopic Neobladder Procedure in Women. <i>Journal of Urology</i> , <b>1995</b> , 154, 2044-2049	2.5	130
2	Lower urinary tract reconstruction following cystectomy in women using the Kock ileal reservoir with bilateral ureteroileal urethrostomy: initial clinical experience. <i>Journal of Urology</i> , <b>1994</b> , 152, 1404-8	2.5	102
1	Cystectomy in the female patient		144-155